Literature DB >> 12669931

A clinical prediction rule for nerve function impairment in leprosy patients-revisited after 5 years of follow-up.

Richard P Croft1, Peter G Nicholls, Ewout W Steyerberg, Jan H Richardus, Steven G Withington, W Cairns S Smith.   

Abstract

Nerve function impairment (NFI) commonly occurs during or after chemotherapy in leprosy. We previously described a clinical prediction rule to estimate the risk of NFI occurring within 2 years of diagnosis, based on 2510 patients who are followed up in the Bangladesh Acute Nerve Damage Study (BANDS). This prediction rule assigns new leprosy patients to one of three risk groups based on leprosy group and the presence or absence of NFI at registration. Updated data with up to 5 years of follow-up showed that 95% of all NFI occurred within 2 years. This study confirms the validity of the rule and supports the conclusion that there is little value for the detection of NFI in extending follow-up beyond 2 years.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12669931

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


  9 in total

1.  Treatment of leprosy.

Authors:  Diana N J Lockwood; Bhushan Kumar
Journal:  BMJ       Date:  2004-06-19

Review 2.  Mycobacterium leprae-host-cell interactions and genetic determinants in leprosy: an overview.

Authors:  Roberta Olmo Pinheiro; Jorgenilce de Souza Salles; Euzenir Nunes Sarno; Elizabeth Pereira Sampaio
Journal:  Future Microbiol       Date:  2011-02       Impact factor: 3.165

3.  Cost-effectiveness of a chemoprophylactic intervention with single dose rifampicin in contacts of new leprosy patients.

Authors:  Willemijn J Idema; Istvan M Majer; David Pahan; Linda Oskam; Suzanne Polinder; Jan Hendrik Richardus
Journal:  PLoS Negl Trop Dis       Date:  2010-11-02

Review 4.  Systematic Review of Survival Analysis in Leprosy Studies-Including the Following Outcomes: Relapse, Impairment of Nerve Function, Reactions and Physical Disability.

Authors:  Celivane Cavalcanti Barbosa; Gilberto Silva Nunes Bezerra; Amanda Tavares Xavier; Maria de Fátima Pessoa Militão de Albuquerque; Cristine Vieira do Bonfim; Zulma Maria de Medeiros; Wayner Vieira de Souza
Journal:  Int J Environ Res Public Health       Date:  2022-09-26       Impact factor: 4.614

5.  Two randomized controlled clinical trials to study the effectiveness of prednisolone treatment in preventing and restoring clinical nerve function loss in leprosy: the TENLEP study protocols.

Authors:  Inge Wagenaar; Wim Brandsma; Erik Post; Wim van Brakel; Diana Lockwood; Peter Nicholls; Paul Saunderson; Cairns Smith; Einar Wilder-Smith; Jan Hendrik Richardus
Journal:  BMC Neurol       Date:  2012-12-18       Impact factor: 2.474

6.  Intraneural injection of corticosteroids to treat nerve damage in leprosy: a case report and review of literature.

Authors:  Sherine G Nashed; Tarek A Rageh; Emad S Attallah-Wasif; Alaa A Abd-Elsayed
Journal:  J Med Case Rep       Date:  2008-12-09

7.  Grade 2 disabilities in leprosy patients from Brazil: Need for follow-up after completion of multidrug therapy.

Authors:  Marcos Túlio Raposo; Martha Cerqueira Reis; Ana Virgínia de Queiroz Caminha; Jörg Heukelbach; Lucy Anne Parker; Maria Pastor-Valero; Maria Ines Battistella Nemes
Journal:  PLoS Negl Trop Dis       Date:  2018-07-16

8.  Effectiveness of 32 versus 20 weeks of prednisolone in leprosy patients with recent nerve function impairment: A randomized controlled trial.

Authors:  Inge Wagenaar; Erik Post; Wim Brandsma; Bob Bowers; Khorshed Alam; Vanaja Shetty; Vivek Pai; Sajid Husain; Cita Rosita Sigit Prakoeswa; Linda Astari; Deanna Hagge; Mahesh Shah; Kapil Neupane; Krishna Bahadur Tamang; Peter Nicholls; Jan Hendrik Richardus
Journal:  PLoS Negl Trop Dis       Date:  2017-10-04

9.  Whole blood RNA signatures in leprosy patients identify reversal reactions before clinical onset: a prospective, multicenter study.

Authors:  Maria Tió-Coma; Anouk van Hooij; Kidist Bobosha; Jolien J van der Ploeg-van Schip; Sayera Banu; Saraswoti Khadge; Pratibha Thapa; Chhatra B Kunwar; Isabela M Goulart; Yonas Bekele; Deanna A Hagge; Milton O Moraes; Rosane M B Teles; Roberta Olmo Pinheiro; Erik W van Zwet; Jelle J Goeman; Abraham Aseffa; Mariëlle C Haks; Tom H M Ottenhoff; Robert L Modlin; Annemieke Geluk
Journal:  Sci Rep       Date:  2019-11-29       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.